Indomethacin inhibits circulating PGE2 and reverses postexercise suppression of natural killer cell activity.
Natural killer (NK) cells are important in combating viral infections and cancer. NK cytolytic activity (NKCA) is often depressed during recovery from strenuous exercise. Lymphocyte subset redistribution and/or inhibition of NK cells via soluble mediators, such as prostaglandin (PG) E2 and cortisol, are suggested as mechanisms. Ten untrained (peak O2 consumption = 44.0 +/- 3.5 ml. kg-1. min-1) men completed at 2-wk intervals a resting control session and three randomized double-blind exercise trials after the oral administration of a placebo, the PG inhibitor indomethacin (75 mg/day for 5 days), or naltrexone (reported elsewhere). Circulating CD3(-)CD16(+)/56(+) NK cell counts, PGE2, cortisol, and NKCA were measured before, at 0.5-h intervals during, and at 2 and 24 h after a 2-h bout of cycle ergometer exercise (65% peak O2 consumption). During placebo and indomethacin conditions, exercise induced significant (P < 0.0001) elevations of NKCA (>100%) and circulating NK cell counts (>350%) compared with corresponding control values. With placebo treatment, total NKCA was suppressed (28%; P < 0.05) 2 h after exercise, and a postexercise elevation (36%; P = 0.02) of circulating PGE2 was negatively correlated (r = 0.475, P = 0.03) with K-562 tumor cell lysis. NK counts were unchanged in the postexercise period, but at this stage CD14(+) monocyte numbers were elevated (P < 0.0001). Indomethacin treatment eliminated the postexercise increase in PGE2 concentration and completely reversed the suppression of total and per CD16(+)56(+) NKCA 2 h after exercise. These data support the hypothesis that the postexercise reduction in NKCA reflects changes in circulating PGE2 rather than a differential lymphocyte redistribution.
Rhind
S G
SG
Defence and Civil Institute of Environmental Medicine, Toronto, Ontario M3M 3B9, Canada.
Gannon
G A
GA
Suzui
M
M
Shephard
R J
RJ
Shek
P N
PN
D000284:Administration, Oral; D000328:Adult; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage*; D003601:Cytotoxicity Tests, Immunologic; D015232:Dinoprostone / Q000097:blood / Q000276:immunology*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000276:immunology; D007213:Indomethacin / Q000008:administration & dosage*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D008297:Male; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D005082:Physical Exertion / Q000502:physiology*
D016861:Cyclooxygenase Inhibitors; D015232:Dinoprostone; D006854:Hydrocortisone; D007213:Indomethacin